HCPCS
J0597
1 unit = 10 IU
Phase 1
Identify what you're billing
The 10 IU unit basis and on-demand-vs-prophy distinction are the top denial drivers.
The 10 IU unit basis — biller error trap CMS HCPCS verified May 2026
J0597 bills 1 unit = 10 IU, NOT 1 unit = 1 IU. Off-by-10 is the most common HAE billing error.
Most specialty drug J-codes use a 1 mg = 1 unit convention (Opdivo J9299, Rituxan J9312, Tecentriq J9022). C1-INH J-codes are different. J0597 (Berinert), J0598 (Cinryze), J0596 (Ruconest), and J0599 (Haegarda) all bill on a 10 IU unit basis. Billing IU as units overstates the claim by 10×.
If you bill IU as units, you will be off by 10×. A 70 kg patient on 20 IU/kg
receives 1,400 IU = 140 units, not 1,400 units. A typical claim line of "J0597 ×
1,400" is an immediate audit flag. Auditors and modern claims systems often catch the error
automatically; payer takebacks for IU-as-units overbilling are common.
Conversion cheat sheet (20 IU/kg dose)
| Patient weight | Total IU (20 IU/kg) | J0597 units | 500 IU vials needed |
|---|---|---|---|
| 25 kg (peds) | 500 IU | 50 units | 1 vial |
| 40 kg (peds/adolescent) | 800 IU | 80 units | 2 vials (200 IU waste) |
| 50 kg | 1,000 IU | 100 units | 2 vials |
| 70 kg | 1,400 IU | 140 units | 3 vials (100 IU waste) |
| 85 kg | 1,700 IU | 170 units | 4 vials (300 IU waste) |
| 100 kg | 2,000 IU | 200 units | 4 vials |
| 120 kg | 2,400 IU | 240 units | 5 vials (100 IU waste) |
Why fixed 500 IU vials matter: Berinert ships only as 500 IU single-dose vials, while dosing
is weight-based at 20 IU/kg. Fractional-vial waste is the rule, not the exception — bill JW with the
wasted units (in 10 IU billing units) on a separate line.
On-demand vs prophylaxis — same molecule, different products FDA label May 2026
Berinert and Cinryze share an active ingredient. Indication, dosing, and HCPCS differ.
Berinert and Cinryze are both pasteurized plasma-derived C1 esterase inhibitor manufactured by CSL Behring. The molecule is identical. The two products are distinct FDA approvals with different J-codes, different labels, and different dosing regimens:
| Berinert (on-demand) | Cinryze (prophylaxis) | |
|---|---|---|
| Active molecule | C1-INH human, pasteurized | C1-INH human, pasteurized (same) |
| HCPCS | J0597 | J0598 |
| FDA indication | Acute attack treatment | Routine prophylaxis |
| Dosing | 20 IU/kg IV at attack onset | 1,000 IU IV every 3–4 days |
| Vial sizes | 500 IU single-dose | 500 IU single-dose |
| Route & rate | IV push, ~5 min (≤ 4 mL/min) | IV infusion, slower |
| Self-admin | Yes (label permits) | Yes (label permits) |
| Manufacturer | CSL Behring | CSL Behring |
| Cross-link | (this page) | Cinryze (J0598) → |
Do NOT interchange J-codes on the claim. If the patient is treated with Berinert vials,
bill J0597. If treated with Cinryze vials, bill J0598. Same molecule does not equal same code.
Submitting J0597 for a routine prophylactic regimen will be denied as off-label, even if the dispensing
pharmacy crossed the products. Document the brand/lot number on the infusion record.
Billing Berinert J0597 for prophylaxis is an automatic denial. The FDA label for Berinert
is on-demand acute-attack treatment. Payers HAE policies (UHC HAE LCD, Aetna CPB 0758, Cigna 0500) all
recognize this distinction. For routine prophylaxis, prescribe a labeled prophy product:
Cinryze J0598 (IV C1-INH), Haegarda J0599
(SC C1-INH), or Takhzyro J0593 (SC lanadelumab).
HAE therapy class — on-demand vs prophylaxis landscape CMS Q2 2026
Six distinct products, three mechanisms, two regimens (on-demand vs prophy). Picking the wrong one is the #1 PA denial.
HAE pharmacotherapy splits cleanly into two regimens (on-demand vs prophylaxis) and three mechanisms (C1-INH replacement, kallikrein inhibition, bradykinin B2 receptor antagonism). Berinert sits squarely in the on-demand C1-INH IV box. Each product below has its own J-code, ICD-10 PA criteria, and payer policy.
HAE class — on-demand products (acute attack treatment)
| Product | HCPCS | Mechanism | Route | Dose | Manufacturer |
|---|---|---|---|---|---|
| Berinert (this page) | J0597 |
Plasma-derived C1-INH | IV push ~5 min | 20 IU/kg | CSL Behring |
| Ruconest | J0596 |
Recombinant C1-INH (rabbit milk) | IV push ~5 min | 50 IU/kg (max 4,200 IU) | Pharming |
| Firazyr / Sajazir (icatibant) | J1744 |
Bradykinin B2 receptor antagonist | SC injection | 30 mg SC (3 mL) | Takeda / Cipla (generic) |
| Kalbitor (ecallantide) | J1290 |
Plasma kallikrein inhibitor | SC (3 sites) | 30 mg (3 × 10 mg) | Takeda |
HAE class — prophylactic products (routine prevention)
| Product | HCPCS | Mechanism | Route | Schedule | Manufacturer |
|---|---|---|---|---|---|
| Cinryze | J0598 |
Plasma-derived C1-INH (same as Berinert) | IV | 1,000 IU q3–4 days | Takeda |
| Haegarda | J0599 |
Plasma-derived C1-INH | SC | 60 IU/kg twice weekly | CSL Behring |
| Takhzyro (lanadelumab) | J0593 |
Anti-plasma-kallikrein mAb | SC | 300 mg q2 weeks (q4 weeks if attack-free 6 mo) | Takeda |
| Orladeyo (berotralstat) | NDC (oral) | Oral plasma kallikrein inhibitor | PO | 150 mg PO daily | BioCryst |
Where Berinert fits: Plasma-derived C1-INH IV on-demand. Competes head-to-head with
Ruconest (recombinant C1-INH) for IV on-demand patients, and with Firazyr/Sajazir (SC bradykinin
antagonist) and Kalbitor (SC kallikrein inhibitor) on the broader on-demand market. Patient choice
often comes down to IV access, prior product tolerability, and self-administration training.
Patients on chronic prophylaxis still need an on-demand product. Even the most effective
prophylaxis (Takhzyro, Haegarda, Cinryze, Orladeyo) does not eliminate breakthrough attacks. US HAEA and
WAO/EAACI guidelines say every HAE patient must have access to a labeled on-demand agent
regardless of their prophylaxis regimen. PA submissions for Berinert in patients also on Takhzyro or
Haegarda should highlight this guideline standard.
Dosing & unit math FDA label May 2026
Weight-based 20 IU/kg dose at first sign of HAE attack. Same dose for any attack site (abdominal, facial, laryngeal).
Dosing parameters
- Standard dose: 20 IU/kg IV at first sign of HAE attack
- Attack site: Abdominal, facial, or laryngeal — same dose for all
- Pediatric: Same dose (20 IU/kg) regardless of age — FDA label includes pediatric patients
- Repeat dosing: If attack does not resolve, additional dose may be considered per label and clinician judgment
- Reconstitution: 500 IU vial + 10 mL sterile water = 50 IU/mL (use within 8 hours)
- Administration: Slow IV injection at ≤ 4 mL/min (~5 minutes total per dose)
- Time to resolution: Median time to onset of relief is approximately 30 minutes in pivotal trials
Worked example — 70 kg adult, abdominal HAE attack
# Patient weight: 70 kg
# Dose: 20 IU/kg
Total IU: 70 × 20 = 1,400 IU
Total billable units (J0597): 1,400 ÷ 10 = 140 units
# Vials needed (500 IU each):
ceil(1,400 ÷ 500) = 3 vials = 1,500 IU
Administered: 1,400 IU = 140 units (JZ if entire vials used)
Wasted: 100 IU = 10 units (JW)
# Reconstitution + administration:
3 vials × 10 mL sterile water = 30 mL total
Volume to administer: 1,400 IU ÷ 50 IU/mL = 28 mL
Push rate: ≤ 4 mL/min → ~7 minutes (round to ~5–10 min clinical reality)
# Per-attack Medicare reimbursement (Q2 2026):
140 units × $76.051 = ~$10,647 drug only
Plus JW 10 units waste: 10 × $76.051 = ~$760.51
Plus 96365 admin (clinic only) at MAC rate
# Dose: 20 IU/kg
Total IU: 70 × 20 = 1,400 IU
Total billable units (J0597): 1,400 ÷ 10 = 140 units
# Vials needed (500 IU each):
ceil(1,400 ÷ 500) = 3 vials = 1,500 IU
Administered: 1,400 IU = 140 units (JZ if entire vials used)
Wasted: 100 IU = 10 units (JW)
# Reconstitution + administration:
3 vials × 10 mL sterile water = 30 mL total
Volume to administer: 1,400 IU ÷ 50 IU/mL = 28 mL
Push rate: ≤ 4 mL/min → ~7 minutes (round to ~5–10 min clinical reality)
# Per-attack Medicare reimbursement (Q2 2026):
140 units × $76.051 = ~$10,647 drug only
Plus JW 10 units waste: 10 × $76.051 = ~$760.51
Plus 96365 admin (clinic only) at MAC rate
Worked example — 100 kg adult, laryngeal HAE attack
# Patient weight: 100 kg, ALL laryngeal attacks treated
Total IU: 100 × 20 = 2,000 IU
Total billable units (J0597): 200 units
Vials needed: 4 × 500 IU = exactly 2,000 IU (no waste)
# Per-attack reimbursement (Q2 2026):
200 units × $76.051 = ~$15,210 drug only
ICD-10: D84.1 + T78.3xxA + attack site documentation
Document laryngeal attack urgency on claim
Total IU: 100 × 20 = 2,000 IU
Total billable units (J0597): 200 units
Vials needed: 4 × 500 IU = exactly 2,000 IU (no waste)
# Per-attack reimbursement (Q2 2026):
200 units × $76.051 = ~$15,210 drug only
ICD-10: D84.1 + T78.3xxA + attack site documentation
Document laryngeal attack urgency on claim
NDC, vial, and reconstitution FDA / DailyMed verified May 2026
Single dosage form: 500 IU lyophilized single-dose vial. Reconstitute with 10 mL sterile water before push.
| Field | Value |
|---|---|
| HCPCS | J0597 — "Injection, C-1 esterase inhibitor (human), Berinert, 10 units" |
| NDC (10-digit format) | 0053-7708-01 — verify against current package insert; CSL Behring labeler 0053 |
| NDC (11-digit billing format) | 00053-7708-01 — N4 qualifier on CMS-1500 24A |
| Vial size | 500 IU single-dose lyophilized powder |
| Diluent | 10 mL sterile water for injection (typically supplied with kit) |
| Reconstituted concentration | 50 IU/mL |
| Use window post-reconstitution | Within 8 hours; do not refrigerate after reconstitution |
| Storage (sealed vial) | 2–8°C refrigerated; or up to 25°C room temp for ≤ 6 months prior to expiry |
| Single-dose container | Yes — JZ/JW required per CMS post-7/1/2023 |
| Benefit | Medical OR pharmacy benefit per plan; specialty pharmacy commonly dispenses for home use |
Verify NDC at billing time. CSL Behring may issue revised NDCs for new package
configurations or kit inclusions (e.g., admin supplies). Always pull the NDC from the actual vial label
being administered, not a stored reference. AssureSupport (1-877-355-IGIV) can confirm the current NDC.
Laryngeal attack urgency — always treat US HAEA / WAO/EAACI verified May 2026
Every laryngeal HAE attack must be treated regardless of presenting severity. Asphyxiation risk is real and historically fatal.
Laryngeal HAE attacks are the leading cause of HAE-related mortality. Pre-on-demand-therapy era case series report case-fatality rates of 15–40% from asphyxiation. With prompt on-demand treatment (Berinert, Ruconest, Firazyr, Kalbitor), fatality is rare but the risk window is short: airway swelling can progress from mild voice change to obstruction within hours.
Always treat every laryngeal attack — regardless of severity at presentation.
Do not wait for stridor, hoarseness escalation, or oxygen desaturation. Treat at first sign of
laryngeal involvement (voice change, throat tightness, dysphagia, anterior neck swelling).
Documentation for laryngeal attacks
- ICD-10: T78.3xxA (angioneurotic edema, initial encounter) + D84.1 (defects in complement system)
- Attack site: Document "laryngeal" or "upper airway" explicitly in the chart and on the claim narrative when possible
- Symptom progression: Voice change, throat tightness, dyspnea, drooling, or stridor
- Urgency rationale: Cite US HAEA / WAO/EAACI guideline standard "always treat laryngeal"
- Disposition: Even with home self-administration, instruct patient to proceed to ED or call 911 simultaneously for any laryngeal attack — on-demand drug is bridge therapy, not a substitute for airway monitoring
Payer PA criteria recognize laryngeal urgency. UnitedHealthcare HAE LCD and Aetna CPB 0758
list laryngeal attacks as automatic medical necessity for on-demand C1-INH — PA review for Berinert
used in laryngeal attacks is typically not a barrier. Document the site clearly on initial PA submission
and on each retrospective claim.
Why Berinert (vs alternatives) for laryngeal attacks
- Speed of action: Median onset of relief ~30 min in pivotal trials — comparable to other on-demand agents
- Self-administration: Patient can self-treat at home at first sign, then go to ED simultaneously — faster overall time-to-treatment than waiting at ED for IV
- Pediatric coverage: Berinert label includes pediatric patients (Firazyr is age-restricted; Kalbitor age 12+)
- IV vs SC trade-off: IV (Berinert/Ruconest) typically faster onset than SC (Firazyr/Kalbitor) for many clinicians' subjective preference, though head-to-head data are limited
Self-administration vs clinic administration — billing impact FDA label / CSL Behring May 2026
Most HAE patients self-treat at home. Billing path is fundamentally different from clinic administration.
Berinert's FDA label permits self-administration after appropriate training. For HAE on-demand, speed-to-treatment is decisive — patients with pre-positioned product at home (or carrying it during travel) self-treat at the first symptom rather than waiting for ED IV access. The billing path differs materially:
| Self-administered at home | Clinic-administered (POS 11/49) | |
|---|---|---|
| Drug source | Specialty pharmacy dispenses to patient (pre-positioned) | Provider buy-and-bill (or 340B if eligible) |
| Drug billing | Specialty pharmacy bills payer (medical or pharmacy benefit) | Provider bills J0597 + JZ/JW |
| Admin CPT | Not billed (patient self-administers) | 96365 for ~5-min IV push |
| POS | 12 (home) on the dispense claim if billed under medical benefit | 11 (office) or 49 (AIC) |
| Benefit | Often pharmacy benefit; sometimes medical with home-delivery | Medical benefit (Part B for Medicare) |
| Storage / dispensing | Patient stores 500 IU vials at home; specialty pharmacy refills | Provider stocks Berinert in clinic inventory |
| Speed-to-treatment | Minutes (patient at home) | Hours (drive + intake + IV access) |
Self-administration is the dominant pathway for HAE on-demand. Most stable HAE patients
on long-term care are trained to reconstitute and self-push Berinert at home. Provider-administered
Berinert is more typical for newly diagnosed patients during training, for patients without IV access
skills, or for patients in a clinic when an attack starts. The billing implication: provider-side J0597
claims are a small fraction of total Berinert utilization.
Do not bill J0597 for self-administered doses. If the drug is dispensed via specialty
pharmacy and the patient self-pushes at home, the specialty pharmacy bills the dispense; the provider
does not bill J0597 or 96365. Submitting both creates a duplicate-billing problem and potential
compliance exposure.
Home infusion vendor scenario is uncommon for on-demand Berinert. Home infusion S-codes
(S9355) and per-visit codes (99601/99602) apply only when a home-infusion nurse administers the drug at
home. For HAE on-demand, the typical home pathway is patient self-administration, not nurse-administered
infusion. Verify the actual administration model before billing.
Phase 2
Code the claim
Non-chemo IV admin (clinic only), JZ on every adult claim, JW for waste, HAE-specific ICD-10.
Administration codes — clinic billing CPT verified May 2026
Berinert is non-chemo and given as an IV push over ~5 minutes. Use 96365 for clinic administration.
| Code | Description | When to use |
|---|---|---|
96365 |
IV infusion, for therapy/prophylaxis/diagnosis (specify substance/drug); initial, up to 1 hour | Primary code for Berinert clinic admin. The 5-minute push falls within "up to 1 hour." |
96374 |
IV push, single or initial substance/drug | Some practices use 96374 for IV push under 15 min. Verify MAC and payer policy — for therapeutic infusions, 96365 is generally preferred even for short pushes; CSL Behring guidance and most HAE LCDs reference 96365. |
96413 / 96415 |
Chemotherapy administration codes | NOT appropriate. Berinert is not chemotherapy. |
99211–99215 |
E/M codes | Use modifier 25 if a separately identifiable E/M is performed same day as the infusion. |
S9355 / 99601 / 99602 |
Home infusion vendor codes | Only when a home-infusion nurse administers Berinert at home. Uncommon for HAE on-demand — most home doses are self-administered (no admin code). |
Single-encounter, single-dose claim: An on-demand Berinert encounter is one visit per
attack. Bill J0597 (with units = total IU ÷ 10), JZ (or JW for waste), and 96365 once per
encounter. Do not bill 96366 unless infusion exceeds one hour (rare for ~5-min push).
Modifiers CMS verified May 2026
JZ — required on virtually every adult claim with no waste
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Berinert vials are 500 IU single-dose lyophilized vials. When the whole vial(s) are used and no drug is discarded, bill JZ on the J0597 line.
JW — partial-vial waste (common for Berinert)
Berinert dosing is weight-based at 20 IU/kg, but vials come only in 500 IU sizes — partial-vial waste is the norm. Example: a 70 kg patient at 1,400 IU requires 3 vials (1,500 IU). The patient receives 1,400 IU = 140 units (JZ on this line); 100 IU = 10 units are wasted (JW on a separate line). One of JZ or JW must be on every J0597 claim.
Pediatric patients especially generate waste. A 25 kg pediatric patient at 20 IU/kg = 500 IU
= 1 full vial (no waste). A 30 kg pediatric patient = 600 IU; needs 2 vials (1,000 IU); 400 IU waste
(40 units JW). Document the discarded amount on the infusion log; bill JW on a separate claim line with
the wasted units.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the Berinert administration. For an HAE acute-attack visit, the triage assessment, attack-site evaluation, and post-administration monitoring may rise to the level of a separately reportable E/M.
340B modifiers (JG, TB)
For 340B-acquired Berinert, follow your MAC's current 340B modifier policy. CSL Behring AssureSupport does not provide 340B-specific modifier instructions; verify with your 340B program coordinator.
ICD-10-CM — HAE coding FY2026 verified May 2026
HAE ICD-10 is a two-code combination: complement defect + acute attack/angioedema.
| Code | Description | Use for |
|---|---|---|
D84.1 |
Defects in the complement system (includes hereditary C1 esterase inhibitor deficiency) | Primary HAE diagnosis code — supports complement-pathway disease (C1-INH deficiency, Type I/II HAE) |
T78.3XXA |
Angioneurotic edema, initial encounter | Acute attack code — identifies the active angioedema episode being treated. Most common combination on Berinert claims. |
T78.3XXD |
Angioneurotic edema, subsequent encounter | Use for subsequent encounter (e.g., repeat dose for the same attack). |
T78.3XXS |
Angioneurotic edema, sequela | Sequela of HAE attack (rarely needed for on-demand billing). |
D84.81 |
Immunodeficiency due to other complement deficiency | Less commonly used — verify payer policy; D84.1 is generally preferred for HAE Type I/II. |
D84.9 |
Immunodeficiency, unspecified | Avoid. Too non-specific for HAE PA approval; use D84.1. |
Standard combination on a Berinert claim:
D84.1 + T78.3XXA.
Add the attack-site narrative (abdominal, facial, laryngeal) in the chart and, when supported by the
claim narrative field, on the submitted claim.
HAE Type III / hereditary angioedema with normal C1-INH function presents differently
and falls outside Berinert's FDA label (which covers Type I and Type II). Some payers will deny
Berinert for HAE Type III without specific clinical justification; document HAE typing (C4, C1-INH antigenic
and functional levels) on the PA submission.
Site of care & place of service Verified May 2026
For HAE on-demand, the dominant site of care is patient home via specialty pharmacy dispense and self-administration. Clinic and ED administration are minority pathways used for newly diagnosed patients during training, for patients without home product, or for severe attacks where the patient seeks emergent care.
| Setting | POS | Claim form | Frequency |
|---|---|---|---|
| Patient home (self-administered) | 12 | Specialty pharmacy dispense (medical or pharmacy benefit per plan) | Dominant — most HAE on-demand utilization |
| Allergy / immunology office | 11 | CMS-1500 / 837P (provider buy-and-bill) | Common during diagnosis, training, or in-clinic attack |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Less common for HAE on-demand (push is brief; chair time minimal) |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Uncommon |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Uncommon |
| Emergency department | 23 | UB-04 / 837I | For severe attacks — especially laryngeal — when patient lacks home product or cannot self-administer |
Most commercial payers do NOT actively site-of-care steer Berinert the way they steer
IVIG. The reason: home self-administration is already the dominant pathway, and the brief 5-minute push
does not generate significant chair-time savings to capture by AIC steering. Verify per-payer for any
recent policy changes.
Claim form field mapping CSL Behring AssureSupport 2025
For provider-administered Berinert (POS 11/49). Self-administered home doses are billed by specialty pharmacy on a different claim form.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + CSL Behring NDC + UN (units) + total IU administered as the NDC quantity |
| HCPCS J0597 + JZ (or JW for waste) | 24D (drug line) | Units = total IU ÷ 10 (NOT total IU) |
| Drug units | 24G | Per the 10 IU unit basis — double-check the math |
| CPT 96365 | 24D (admin line) | One unit per encounter (single ~5-min push) |
| JW waste line | 24D (separate line) | If partial-vial waste: J0597 + JW + wasted units (in 10 IU billing units) |
| ICD-10 | 21 | D84.1 + T78.3XXA typical combination |
| PA number | 23 | Required by virtually all major payers for Berinert |
| Place of service | 32 / box 24B | 11 (office), 49 (AIC), 23 (ED) most common provider sites |
Phase 3
Get paid
PA is universal; HAE typing documentation and on-demand-vs-prophy distinction are the recurring battlegrounds.
Payer policy snapshot Reviewed May 2026
All major payers require PA for Berinert. HAE Type I/II diagnosis documentation is mandatory; on-demand-only label is enforced.
| Payer | PA? | Key criteria | On-demand-only enforcement |
|---|---|---|---|
| UnitedHealthcare HAE Medical Coverage Policy / LCD |
Yes | HAE Type I or II confirmed (low C4 + low C1-INH antigenic [Type I] or low C4 + low C1-INH function [Type II]); attack documentation; appropriate dosing | Yes — J0597 for prophy is denied; redirect to Cinryze, Haegarda, or Takhzyro |
| Aetna CPB 0758 (Hereditary Angioedema) |
Yes | HAE Type I/II confirmed; on-demand for acute attacks only | Yes — on-demand vs prophy split per FDA labels |
| Cigna Coverage Policy 0500 (HAE) |
Yes | HAE Type I/II; quantity limits per attack and per month | Yes — quantity-limit denials common if patient appears to be using J0597 prophylactically |
| BCBS plans Vary by plan |
Yes | Plan-specific; most align with FDA label and require HAE typing | Plan-specific; prophy use generally denied |
| Medicare (MAC LCDs) No NCD; MAC LCDs |
Generally not (Medicare is fee-for-service for J-codes); PA may apply for Medicare Advantage | Coverage per FDA-labeled indication; ICD-10 D84.1 + T78.3xxA standard | Yes via documentation requirement |
Quantity limits — common payer pattern
Many commercial payers impose quantity limits per month on Berinert (e.g., 4–8 attacks-worth of dose per month) under the assumption that on-demand utilization should be episodic. Patients with high attack frequency may exceed QL and trigger an exception review — this is often the trigger for transitioning to prophylaxis (Takhzyro, Haegarda, Cinryze, or Orladeyo) while keeping Berinert on hand for breakthrough attacks.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J0597
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6% per unit
$76.051
per 10 IU unit
Per IU basis
$7.61
$76.051 ÷ 10
70 kg dose (1,400 IU = 140 units)
$10,647.14
20 IU/kg attack treatment
25 kg pediatric (500 IU = 50 units)
$3,802.55
1 vial, no waste
100 kg dose (2,000 IU = 200 units)
$15,210.20
4 vials, no waste
Annual (10 attacks/yr, 70 kg)
$106,471.40
Drug cost only; varies with attack frequency
Coverage: No NCD specific to Berinert. Coverage falls under MAC LCDs for HAE on-demand
therapy. All MACs cover J0597 for FDA-labeled acute-attack indications with appropriate ICD-10
documentation (D84.1 + T78.3XXA). Medicare Advantage plans typically apply commercial-style PA.
Code history
- J0597 — permanent code, "Injection, C-1 esterase inhibitor (human), Berinert, 10 units"
- The 10 IU billing unit applies to all C1-INH J-codes (J0596 Ruconest, J0597 Berinert, J0598 Cinryze, J0599 Haegarda)
Patient assistance — CSL Behring AssureSupport & Berinert programs CSL Behring verified May 2026
- Berinert direct support line: 1-855-999-3273 — product-specific assistance
- CSL Behring AssureSupport: 1-877-355-IGIV (1-877-355-4448) — benefits investigation, prior authorization assistance, appeals support, financial assistance navigation
- Berinert Co-pay Program (commercial): commercially insured patients may qualify for $0 first-dose copay and ongoing copay support; excludes Medicare, Medicaid, federal program patients
- CSL Behring Patient Assistance Program: free product for eligible uninsured / underinsured patients meeting income requirements
- Foundations (Medicare patients): US HAEA, PAN Foundation, HealthWell Foundation, Patient Advocate Foundation — verify open HAE funds quarterly
- US HAEA (advocacy): 1-866-798-5598 — patient education, advocacy, regional events, financial assistance navigation
- Reimbursement support: CSL Behring AssureSupport provides PA assistance, denial-management support, appeal letter templates
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J0597 pre-loaded.
Phase 4
Fix problems
Unit-basis errors, prophy-vs-on-demand mismatches, and HAE typing documentation are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units billed exceed reasonable | Billed IU as units instead of dividing by 10 | Divide total IU by 10. 1,400 IU dose = 140 units, NOT 1,400 units. Correct the claim and resubmit. |
| Off-label use (denied as prophylaxis) | J0597 submitted for routine prophylactic regimen | Berinert is on-demand only. For prophy, prescribe Cinryze (J0598), Haegarda (J0599), or Takhzyro (J0593) and bill the correct code. If acute treatment was the actual indication, resubmit with attack documentation. |
| HAE typing not documented | D84.1 alone without C4 / C1-INH lab documentation | Submit lab results: low C4 + low C1-INH antigenic level (Type I) or low C4 + low C1-INH function (Type II). Some payers also accept genetic confirmation (SERPING1 mutation). |
| Wrong admin code (96413/96415) | Chemo IV billed instead of therapeutic IV | Resubmit with 96365. Berinert is non-chemo — chemo admin codes do not apply. |
| JZ missing on adult claim | Single-dose vial claim without JZ when no waste | Resubmit with JZ. Required since 7/1/2023 on every claim with no waste. |
| JW missing despite partial-vial waste | Wasted drug not reported when vial(s) exceed dose | Add JW line for discarded units (in 10 IU billing units). Most weight-based Berinert doses generate waste; document on the infusion log. |
| Quantity limit exceeded | Patient exceeding monthly attack-equivalent QL | If true high attack frequency, submit for QL exception with attack diary; consider transitioning to prophylaxis (Takhzyro / Haegarda / Cinryze / Orladeyo). |
| Duplicate billing (provider + specialty pharmacy) | Provider billed J0597 + 96365 for a dose that was actually self-administered by patient | Identify the actual dispense path. Self-administered home doses are billed by specialty pharmacy only; provider should not bill J0597 + 96365 for those doses. Reverse the duplicate provider claim. |
| Brand mismatch (Berinert billed when Cinryze was given) | HCPCS does not match the product administered | Verify the actual vial(s) used. Berinert vials are J0597; Cinryze vials are J0598. Same molecule, different products. Correct the J-code based on the actual lot. |
| HAE Type III not on label | Berinert prescribed for HAE with normal C1-INH function | Submit clinical justification or consider alternative agent on-label for HAE Type III (icatibant has been used in some cases off-label). |
Frequently asked questions
What is the HCPCS code for Berinert?
Berinert is billed under HCPCS J0597 — "Injection, C-1 esterase inhibitor (human),
Berinert, 10 units." Critically, 1 unit = 10 IU (NOT 1 IU as a biller might assume).
A 70 kg patient receiving 20 IU/kg = 1,400 IU bills as 140 units, not 1,400 units.
How many units do I bill for a Berinert dose?
Divide total IU administered by 10. Example: a 70 kg patient at 20 IU/kg = 1,400 IU = 140 units J0597. A 100 kg patient = 2,000 IU = 200 units. Berinert ships in 500 IU single-dose vials, so dose-rounding may produce waste — bill JZ when no waste, JW with the wasted units when partial-vial discard occurs.
Is Berinert used for HAE prophylaxis?
No. Berinert is FDA-approved on-demand for treatment of acute HAE attacks (abdominal, facial, laryngeal) only — NOT for routine prophylaxis. Prophylactic C1-INH IV is Cinryze (J0598), which is the same plasma-derived molecule with a different FDA-labeled indication. Subcutaneous prophylaxis options include Haegarda (C1-INH SC, J0599) and Takhzyro (lanadelumab SC, J0593). Billing Berinert J0597 for prophylactic use will trigger denials.
What is the difference between Berinert and Cinryze?
Same active molecule (plasma-derived C1 esterase inhibitor, human, pasteurized — both made by CSL Behring), different FDA-labeled indications and different HCPCS codes. Berinert (J0597) is on-demand acute-attack treatment at 20 IU/kg IV. Cinryze (J0598) is routine prophylaxis at 1,000 IU IV every 3–4 days. Do not interchange the two on a claim — the J-code, indication, and dosing schedule must match the product administered.
Should every laryngeal HAE attack be treated?
Yes — always. Laryngeal HAE attacks are life-threatening because progressive laryngeal swelling can cause asphyxiation. US HAEA and WAO/EAACI guidelines say every laryngeal attack must be treated with on-demand C1-INH (or alternative on-demand agent) regardless of severity at presentation. Document the attack site (laryngeal) and clinical urgency on the claim. Payer prior-auth criteria recognize laryngeal attacks as automatic medical necessity for on-demand therapy.
Can patients self-administer Berinert at home?
Yes. The FDA label permits self-administration after appropriate training, and most HAE patients on-demand prescriptions are pre-positioned at home or with the patient for use at first sign of an attack — speed of treatment matters for outcomes. Billing shifts when the drug is self-administered: it is typically dispensed via specialty pharmacy under the medical or pharmacy benefit (depending on plan), and the provider does not bill J0597 + administration. When administered in a clinic, the provider bills J0597 (for the drug) plus 96365 (therapeutic IV, non-chemo) for the ~5-minute push.
What administration CPT do I use for Berinert in a clinic?
CPT 96365 (initial hour, therapeutic IV) — Berinert is non-chemo and given as a slow
IV push over approximately 5 minutes. Even though the infusion is brief, 96365 is the appropriate code
for non-chemo IV. For self-administered home doses, the provider does not bill 96365 — the drug is
dispensed and the patient (or trained caregiver) administers it.
What is the Medicare reimbursement for J0597?
For Q2 2026, the Medicare Part B payment limit for J0597 is $76.051 per 10 IU unit (ASP + 6%) — equivalent to approximately $7.61 per IU. A 70 kg patient at 20 IU/kg (1,400 IU = 140 units) reimburses approximately $10,647.14 per acute attack treatment before sequestration. ASP is updated quarterly by CMS.
Do I need prior authorization for Berinert?
Yes — virtually all commercial and Medicare Advantage plans require PA for Berinert. PA criteria typically require: (1) confirmed HAE Type I or Type II diagnosis (low C4 with low C1-INH antigenic level [Type I] or low C4 with low C1-INH function [Type II]), (2) documentation that the prescription is for acute-attack treatment (not prophylaxis), (3) attack site documentation when treating, and (4) appropriate dosing. Laryngeal attacks are recognized as automatic medical necessity by most HAE LCDs.
Where does Berinert sit in the HAE class?
Berinert is the plasma-derived C1-INH IV on-demand agent. The on-demand class also includes Ruconest (J0596, recombinant C1-INH IV), Firazyr/Sajazir (J1744, icatibant SC, bradykinin B2 antagonist), and Kalbitor (J1290, ecallantide SC, plasma kallikrein inhibitor). For prophylaxis, the class includes Cinryze (J0598, IV C1-INH — same molecule as Berinert), Haegarda (J0599, SC C1-INH), Takhzyro (J0593, SC mAb), and Orladeyo (oral plasma kallikrein inhibitor). See full HAE class comparison ↑
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- CSL Behring — Berinert HCP/patient site & AssureSupport materials
- DailyMed — Berinert prescribing information (current FDA label)
- CMS — Medicare Part B Drug ASP Pricing File
- US Hereditary Angioedema Association (US HAEA) — patient and clinician resources
- WAO/EAACI Guideline — The international WAO/EAACI guideline for the management of hereditary angioedema (2021 revision)
- UnitedHealthcare — HAE Medical Coverage Policy / LCD
- Aetna CPB 0758 — Hereditary Angioedema (HAE)
- Cigna Coverage Policy 0500 — Hereditary Angioedema
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| HAE class comparison | Quarterly | Refreshed alongside ASP file; tracks Berinert vs Cinryze vs Ruconest vs Haegarda vs Takhzyro positioning. |
| Payer policies (UHC, Aetna, Cigna, BCBS) | Semi-annual | Manual review against published payer HAE policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, indication list | Event-driven | Tied to manufacturer document version + FDA label revision date. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited
source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: CSL Behring AssureSupport 2025. FDA label: Berinert acute HAE attack indication (Type I & II), pediatric included, self-administration permitted. HAE class comparison includes Berinert, Cinryze, Ruconest, Haegarda, Takhzyro, Firazyr, Kalbitor, Orladeyo.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list is verified against the current FDA label revision for Berinert and HAE class comparators.